Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ketoconazole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ketoconazole tablet + AZD1305 Extended Release tablet |
| 2 | EXPERIMENTAL | Verapamil Extended Release tablet + AZD1305 Extended Release tablet |
| 3 | EXPERIMENTAL | AZD1305 Extended Release tablet |
| Name | Type | Description |
|---|---|---|
| Ketoconazole | DRUG | Tablet, administered as repeated doses. |
| Verapamil | DRUG | Extended Release tablet, administered as repeated doses. |
| AZD1305 | DRUG | Extended Release tablet, administered as a single dose. |
Inclusion Criteria: * A body mass index (BMI=weight/height2) of 19 to 30 kg/m2 Exclusion Criteria: * Potassium outside normal reference values * ECG findings outside normal range
Ketoconazole is a small molecule drug being developed by AstraZeneca PLC (ticker: AZN). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied in a clinical trial to assess its interaction with verapamil and AZD1305.
Ketoconazole is being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial that enrolled 27 male participants in Germany. The trial was designed to investigate the interaction of ketoconazole and verapamil with AZD1305.
Ketoconazole is being developed by AstraZeneca PLC, which is listed on the stock exchange under the ticker AZN. The drug is currently in Phase 1 clinical development, with a completed trial involving healthy volunteers.
Ketoconazole is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in healthy volunteers. The single clinical trial for this drug has been completed.
Ketoconazole has one completed clinical trial, NCT00707551, titled "An Interaction Study of Ketoconazole/Verapamil Versus AZD1305." This Phase 1 trial enrolled 27 healthy male participants in Germany and was a controlled, randomized study.